Doxorubicin of Boryung Pharm to obtain COS in Europe

Published: 2002-04-04 06:57:00

Updated: 2002-04-04 06:57:00

Boryung Pharm has recently won the Certificate of Suitability (COS) of doxorubicin, antineoplastic substance, which was successfully developed via its own fermentation process for the third time in the world. It plans to make its indirect export through Helm of Germany, while moving forward its d...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK